Abstract:BACKGROUNDAngiogenesis is closely associated with angiogenesis-dependent diseases including cancers and ocular diseases. Anti-angiogenic therapeutics have been focusing on the (VEGF)/VEGFR signaling axis. However, the clinical resistance, high cost and frequent administration of anti-VEGF drugs make it urgent to discover novel angiogenic pathways.VE-PTP (ptprb) is a novel target with great anti-angiogenic potential. However, it is unclear whether upstream signaling pathways targeting VE-PTP exist in angiogenesis.METHODSWhole genome and embryo transcriptome sequencing were applied to discover the new genenxhl. Transgenic zebrafish model, morpholino knockdown and small interfering RNA were used to explore the role ofnxhlin angiogenesis bothin vitroandin vivo. RNA pulldown, RIP and ChIRP-MS were used to identify interactions between RNA and protein.RESULTSWe discovered a novel zebrafish genenxhlwhich is a homologue of the conserved genenxhthat co-expressed with some key genes essential for embryo development in vertebrate.Nxhldeletion causes angiogenesis defects in embryo. Moreover,nxhlis essential to mediate effects of angiogenesisin vivoandin vitro, andptprbdepletion duplicates the phenotypes ofnxhldeficiency. Importantly,nxhlacts upstream ofptprband regulates many extreme importantptprb-linked angiogenic genes by targeting VE-PTP (ptprb) through interactions with NCL. Notably,nxhldeletion decreases the phosphorylation of NCL T76 and increases the acetylation of NCL K88, suggestingnxhlmay regulate downstream VE-PTP signaling pathways by mediation of NCL posttranslational modification. This is the first description of the interaction betweennxhland NCL, NCL and VE-PTP (ptprb), uncovering a novelnxhl-NCL-VE-PTP signaling pathway on angiogenesis regulation.CONCLUSIONSOur study identifiesnxhlcontrolling angiogenesis by targeting VE-PTP through interactions with NCL, uncovering novel upstream controllers of VE-PTP. Thisnxhl-NCL-VE-PTP pathway may be a therapeutic target in the treatment of angiogenesis-dependent diseases.Clinical PerspectiveWhat Is New?We report a novelnxhl-NCL-VE-PTP signaling pathway that controls angiogenesis.We for the first time demonstrate thatnxhlinteracts with NCL which simultaneously binds to VE-PTP that plays key roles on EC adherens junction, integrity and vascular homeostasis.Nxhlalso controls some other crucial VE-PTP-linked downstream angiogenic genes (such as Tie2, VEGFaa, VEGFR2, Erbb2, S1pr1 and Hey2) which explain the phenotypes induced by thenxhldeficiency.Our study indicates the key role ofnxhlon controlling angiogenesis as an upstream regulator of VE-PTP.What Are the Clinical Implications?There are several ongoing researches investigating the utility of VE-PTP or NCL inhibitors on treatment of angiogenesis-dependent diseases including a range of cancers and nonneoplastic diseases, such as AMD, DME, RA and atherosclerosis.Targeting thenxhl-NCL-VE-PTP pathway may facilitate therapeutic angiogenesis in patients with cancers or ocular diseases such as DME.Our study highlights the great potential ofnxhlon anti-angiogenic therapeutics by targeting VE-PTP.

Genome-wide profiling of angiogenic cis -regulatory elements unravels cis -regulatory SNPs for vascular abnormality

Functional Interrogation Of Enhancer Connectome Prioritizes Candidate Target Genes At Ovarian Cancer Susceptibility Loci

Integrated genomic analysis identifies novel low-frequency <i>cis</i>-regulatory variant rs2279658 associated with VSD risk in Chinese children

A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies.

Systematic identification of regulatory variants associated with cancer risk

Regsnps-Asb: A Computational Framework for Identifying Allele-Specific Transcription Factor Binding from ATAC-seq Data

Molecular Mechanisms of Coronary Disease Revealed Using Quantitative Trait Loci for TCF21 Binding, Chromatin Accessibility, and Chromosomal Looping

Next-generation Sequencing Identifies Novel Genes with Rare Variants in Total Anomalous Pulmonary Venous Connection

Genome-wide enhancer-gene regulatory maps link causal variants to target genes underlying human cancer risk

Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer

Whole Genome and Embryo Transcriptome Analysis of Vertebrate Identifies<i>nxhl</i>Controlling Angiogenesis by Targeting VE-PTP

A novel transcriptional complex on the VE-cadherin promoter regulated the downregulation of VE-cadherin in the Down Syndrome Candidate Region 1 isoform 1L-mediated angiogenesis

Comprehensive characterization genetic regulation and chromatin landscape of enhancer-associated long non-coding RNAs and their implication in human cancer

Comprehensive identification of coronary artery disease-associated variants regulating vascular smooth muscle cell gene expression

Mapping cis -regulatory chromatin contacts in neural cells links neuropsychiatric disorder risk variants to target genes

Critical gene signature and immunological characterization in peripheral vascular atherosclerosis: novel insights from mendelian randomization and transcriptomics

High-Resolution Regulatory Maps Connect Vascular Risk Variants to Disease-Related Pathways

Identification of candidate causal cis -regulatory variants underlying electrocardiographic QT interval GWAS loci

Characterising Cis-Regulatory Variation in the Transcriptome of Histologically Normal and Tumour-Derived Pancreatic Tissues.

Functional Screenings Identify Regulatory Variants Associated with Breast Cancer Susceptibility

Integrating Expression-Related SNPs into Genome-Wide Gene- and Pathway-Based Analyses Identified Novel Lung Cancer Susceptibility Genes.